Actavis CEO and key strategist 1999 to 2008
Under Wessman‘s leadership Actavis became a leading force in the generic pharmaceutical industry. He changed the company from a small local industry player to the 4th largest global generic company operating in 55 countries.
Alvogen Executive Chairman and CEO 2009-currently
As founder and CEO, Wessman has led Alvogen from being a small US based contract manufacturing business to becoming a top 15 global generics player operating in 35 countries in only six years.
Alvogen has received multiple industry recognitions including CPhI Company of the Year Awards and multiple service awards. Development of a balanced yet specialized portfolio consisting of 500 marketed products, as well as a deep pipeline of high-value products in development, is at the core of Wessman’s strategy enabling Alvogen to proactively respond to market needs and fuel sustainable and profitable growth.
Alvotech Founder and Chairman
Alvotech is Biopharmaceutical Company with fully integrated R&D, API and fill and finish capabilities with a brand new state-of-the art facilities. Alvotech has 7 biosimilars in the pipeline with the first product launches scheduled in 2019 at patent expiry.
Operational experience and record growth
Companies led by Wessman have a collective CAGR of more than 60 percent. He has led over 50 strategic acquisitions and partnerships and established operations in over 60 countries around the globe. These companies have achieved very strong organic growth in combination with external growth.
Wessman’s achievements have made him the subject of two Harvard Business School Case Studies, titled “Robert Wessman and the Actavis Winning Formula” (2008) and “Alvogen” (2015).